61 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
4 Feb 22
Purple Biotech Issues Letter to Shareholders
8:31am
toward our goals and want to take this moment to share highlights of this year.
Strategy
Our strategic approach continues to be the development … -inhibition MOA approach of both IRS and STAT3.
Collaborations and partnerships continue to be a strong element of our development strategy. In 2021, we
6-K
EX-99.1
PPBT
Purple Biotech Ltd
2 Oct 19
Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board
8:49am
of directors.
Dr. Rowinsky joins Kitov’s Board with extensive cancer research and drug development experience, oncology and corporate strategy … of experience in corporate strategy, academia, research and drug development in the oncology space. He has been the Executive Director and President
6-K
EX-99.1
PPBT
Purple Biotech Ltd
11 Oct 19
Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of ConsensiTMin the U.S
9:02am
and access to thousands of pharmacies to drive the launch of the drug. In addition, a marketing plan and pricing strategy have been finalized … to the launch of ConsensiTM in the U.S., we are excited about Coeptis’ commercialization strategy and welcome Coeptis’ new partners who have an established
6-K
EX-99.1
PPBT
Purple Biotech Ltd
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
of this new patent marks another step forward in our global intellectual property strategy. China is a large and important market opportunity for us
424B3
PPBT
Purple Biotech Ltd
19 Oct 23
Prospectus supplement
4:40pm
of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees
6-K
EX-99.1
9kdt1z
3 Sep 19
Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
8:23am
6-K
EX-99.1
4zzjnk2
10 Sep 19
Thank you Corporate Presentation September 2019
9:32am
424B3
8up0bk
2 Oct 19
Prospectus supplement
9:37am
6-K
vl7alvu a4z
2 Oct 19
Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board
8:49am
6-K
EX-99.1
hiuu1hj0d 7gkt
22 Oct 21
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy
6:02am
6-K
EX-99.1
5jw8rgbx
3 Mar 21
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
8:23am
6-K
EX-99.1
f0mxz3
2 Nov 22
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
7:39am
6-K
EX-99.1
av2ck
9 Dec 21
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
7:30am
6-K
EX-99.1
i1gzcw1
18 Oct 19
Thank you Corporate Presentation October 2019
4:09pm
6-K
EX-99.1
sr2m 5jbqgqe5
9 Jan 20
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
9:03am
6-K
EX-99.1
fwi8 qngp
4 Jun 21
Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
8:01am
6-K
EX-99.1
2n26foxlmfdl4 9hx3sj
19 Apr 23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
8:17am
6-K
EX-99.1
0oytsa1h6
2 May 24
Report of Foreign Private Issuer
4:13pm
6-K
EX-99.1
wjo3 mfdjvgd8rls
16 May 19
Report of Foreign Private Issuer
7:30am
424B3
tk7i34ifhu8vof
27 Dec 19
Prospectus supplement
4:30pm